DIA maakt ontvangers bekend van presidentsprijs wereldgezondheid
Array
DIA maakt vandaag bekend dat het Center for the AIDS Program of Research in South Africa (CAPRISA) de winnaar is van de inaugurele President’s Award for Outstanding Achievement in World Health (presidentsprijs voor buitengewone prestaties in wereldgezondheid) van DIA. Dit vanwege zijn baanbrekende onderzoek naar een gelvariant van het antiretroviraal medicijn Tenofovir, ter voorkoming van HIV-infecties bij vrouwen. De prijs wordt uitgereikt tijdens de plenaire sessie van de DIA 2011, getiteld: Convergence of Science, Medicine, and Health. Deze wordt gehouden op 20 juni in Chicago, Illinois.
Engelstalig bericht:
DIA Announces Recipients of the Inaugural President’s Award for Outstanding Achievement in World Health
HORSHAM, Pa.–(BUSINESS WIRE)– 20110531 —
DIA today announced the Center for the AIDS Program of Research in South Africa (CAPRISA) winner of the inaugural DIA President’s Award for Outstanding Achievement in World Health for its groundbreaking research on the gel form of the antiretroviral drug, Tenofovir, for the prevention of HIV infection in women. The award will be presented during the plenary session at DIA 2011: Convergence of Science, Medicine, and Health on June 20 in Chicago, IL.
The DIA President’s Award for Outstanding Achievement in World Health recognizes the significant and innovative contributions of an individual, group of individuals, or organization to the improvement of world health. DIA is recognizing the seven scientists who comprised the leadership team of the study (known as CAPRISA 004) which provided the first evidence that antiretroviral drugs can prevent the sexual transmission of HIV in women. The CAPRISA 004 trial, conducted on 889 South African women, demonstrated that the tenofovir microbicide gel used before and after sex reduced the risk of acquiring infection by 39% overall and by 54% in the women who used it consistently. This study was jointly funded by the Governments of South Africa and the United States, through the Technology Innovation Agency (TIA) and the US Agency for International Development (USAID), respectively.
“CAPRISA 004 has been recognized as one of the top research studies of 2010,†says DIA Worldwide Executive Director Paul Pomerantz. “As we continue our commitment to providing patients with access to quality medicines, DIA is proud to present the inaugural President’s Award for Outstanding Achievement in World Health to the CAPRISA Leadership Team.â€
The CAPRISA 004 team includes:
Dr. Salim S. Abdool Karim, Director, CAPRISA
Dr. Quarraisha Abdool Karim, Associate Scientific Director, CAPRISA
Dr. Willard Cates Jr, President, Research, FHI
Dr. Henry Gabelnick, Executive Director, CONRAD
Dr. Carl Montague, General Manager of Health at the Technology Innovation Agency (TIA)
Dr. James Rooney, Vice President of Medical Affairs at Gilead Sciences
Dr. Jeff Spieler, Senior Technical Advisor in Science and Technology in Population and Reproductive Health (PRH) at USAID
“The CAPRISA 004 trial provides new hope for women who bear the brunt of the HIV epidemic in Africa. When implemented, it could have a profound impact on the course of this epidemic,†said Study Co-principal Investigator Dr. Salim S. Abdool Karim, Director of CAPRISA and Pro Vice-Chancellor (Research) of the University of KwaZulu-Natal, South Africa. “This breakthrough would not have been possible without the close collaboration between the three South African and the three US partners who led this study; I am proud and honored to receive this award on behalf of this remarkable team.â€
ABOUT DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India and Beijing, China. (www.diahome.org)
ABOUT CAPRISA
CAPRISA (www.caprisa.org) is an AIDS research institute of the University of KwaZulu-Natal and Columbia University. Its headquarters are at the Nelson R Mandela School of Medicine, University of KwaZulu-Natal in Durban, South Africa. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research. The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV pathogenesis, prevention and epidemiology, as well as the links between tuberculosis and AIDS care. CAPRISA comprises four research programmes: HIV pathogenesis & vaccines, HIV and TB treatment, Microbicides, and HIV prevention and epidemiology.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6740774&lang=en
